Drugs / DWC202213
last change Jun 2023 re-read 2 minutes ago

DWC202213

Developed for
type 2 diabetes mellitus
Investigated by
Daewoong Pharmaceutical Co. LTD.

Trials 1 · a red edge is where a trial was stopped

2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05737771 Jan → Mar 2023 type 2 diabetes mellitus Daewoong Pharmaceutical Co. LTD. Unknown No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as DWC202213 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05737771